A 24 week phase 2b dose range finding study of RTB101 alone or in combination with RAD001 on the incidence of RTI in elderly subjects at increased risk of RTI-related morbidity and mortality.

Trial Profile

A 24 week phase 2b dose range finding study of RTB101 alone or in combination with RAD001 on the incidence of RTI in elderly subjects at increased risk of RTI-related morbidity and mortality.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Jul 2018

At a glance

  • Drugs Dactolisib (Primary) ; Everolimus
  • Indications Respiratory tract infections
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 25 Jul 2018 Primary endpoint of Percentage of patients with one or more laboratory-confirmed respiratory tract infections (RTIs), in the RTB101 in combination with everolimus has not been met, according to a resTORbio media release.
    • 25 Jul 2018 Top-line results presented in a resTORbio Media Release.
    • 09 May 2018 Status changed from recruiting to active, no longer recruiting, according to a resTORbio media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top